LEXINGTON, Ky.--(BUSINESS WIRE)--Intralink-Spine, Inc. (ILS) is pleased to announce the completion of the phase 1 long-term large-animal in vivo testing for the Réjuve treatment for lower back pain.
“Réjuve creates permanent molecular bonds, so we’re hopeful that two, perhaps even one set of injections are all a patient will ever need to receive permanent lower back pain relief”
“The purpose of this study was to verify and validate the final design and safety of the Réjuve device in a six month large-animal (sheep) model. The sheep received fluoroscopic image-guided injections of Réjuve in two lumbar intervertebral discs, with two posterolateral injections per treated level,” states Dr. Tom Hedman. “No infections, clinically relevant or chronic inflammation, or behavioral or neuromuscular effects were seen in the animals over the course of the six month study. This study showed that the procedure to inject Réjuve is safe and can be effectively administered using only standard fluoroscopic techniques.”
According to Lyle Hawkins, CEO of Intralink-Spine, “This is another significant milestone for the Réjuve treatment. This study clearly shows the safety and simplicity of the Réjuve treatment. We’re excited about these results and what this treatment means to those suffering from lower back pain; Réjuve is truly going to be a disruptive breakthrough for the treatment of lower back pain.” Learn more at www.IntralinkSpine.com.
According to Dr. Hedman, CSO of Intralink-Spine and a leading researcher in soft-tissue biomechanics, “Réjuve works in the same manner as the body’s natural response to heal instability and degradation of the spinal disc. The Réjuve device immediately strengthens and stabilizes the disc upon injection to reduce the pain of the patient and eliminate future episodes of debilitating back pain.”
“Réjuve creates permanent molecular bonds, so we’re hopeful that two, perhaps even one set of injections are all a patient will ever need to receive permanent lower back pain relief”, says Hawkins. “And, Réjuve is a much simpler and less expensive treatment than what is being considered with stem cells.”
About 80 percent of the adults in the U.S. experience significant back pain at some point in their life and most back pain sufferers find no relief. In fact, low back pain (LBP) is a challenging condition to treat and one of the most common health problems in the United States for a host of reasons including widespread obesity, an aging population, job related activities or inactivity, and smoking.
Contacts
Intralink-Spine, Inc.
Lyle Hawkins, 502-419-8099
LHawkins@IntralinkSpine.com
Help employers find you! Check out all the jobs and post your resume.
